Keara Stewart, NP

Dr. Cynthia Tsay is an Assistant Professor of Medicine at Weill Cornell Medicine and New York-Presbyterian Hospital and a general gastroenterologist with a clinical and research interest in early gastric cancer, gastric intestinal metaplasia, and other conditions involving the stomach. She is interested in the application of machine learning and artificial intelligence in the risk stratification and early detection of premalignant lesions in high risk populations, as well as the role of the microbiome in these conditions and ways in which medications alter the gastrointestinal microbiome. She has published in Gastroenterology, Clinical Gastroenterology and Hepatology, Alimentary Pharmacology & Therapeutics and the American Journal of Gastroenterology. She obtained her B.A. in the History of Science and the History of Medicine at Yale College and her M. Phil in the History, Philosophy, and Sociology of Science, Medicine, and Technology at the University of Cambridge. Dr. Tsay returned to New Haven where she earned her M.D. at the Yale School of Medicine and completed her residency in Internal Medicine at Yale New Haven Hospital. She also has a M.P.H in Epidemiology from the Harvard T.H. Chan School of Public Health. She completed her fellowship training in Gastroenterology and Hepatology at the Johns Hopkins Hospital where she served as chief fellow during her last two years. Dr. Tsay is also passionate about medical education and the experience of trainees, having served as president of the Yale Resident and Fellow Senate and the chair of the Johns Hopkins Clinical Fellows Council.

Michal Bar-Natan, MD, is Associate Professor of Clinical Medicine and a member of the Leukemia Program at Weill Cornell Medicine and NewYork-Presbyterian Hospital in New York City. Dr. Bar-Natan graduated cum laude from the Sackler School of Medicine. She completed her Internal Medicine Residency at Sheba Medical Center and her Fellowship in Hematology and Medical Oncology at NYU Langone Health. In addition to her clinical fellowship training, Dr. Bar-Natan completed a research fellowship at Dana Farber Cancer Institute and Brigham and Women’s Hospital (Harvard Medical School) with a focus on the role that signal transducer and activator of transcription (STAT) proteins play in the development and treatment of myeloproliferative neoplasms (MPNs) and leukemias.Prior to this position Dr. Bar-Natan served as Associate Professor of Medicine at the Icahn School of Medicine at Mt. Sinai, an Attending Physician with the Center of Excellence for Blood Cancers and Myeloid Disorders, and as the leader of the Acute Lymphoblastic Leukemia program at the Mt. Sinai Tisch Cancer Institute. Dr. Bar-Natan’s focus is on translational research in malignant hematology, particularly myeloid malignancies and acute lymphoblastic leukemia, and the development of investigator-initiated clinical trials for patients with these conditions. She leads early phase clinical trials implementing new therapeutic approaches, such as immunotherapies and combination therapies, and serves as the PI and co-investigator on many clinical trials for acute leukemias and myeloproliferative neoplasms.